FGF21 does not require adipocyte AMP-activated protein kinase (AMPK) or the phosphorylation of acetyl-CoA carboxylase (ACC) to mediate improvements in whole-body glucose homeostasis

• Main Authors: Emilio P. Mottillo (Author), Eric M. Desjardins (Author), Andreas M. Fritzen (Author), Vito Z. Zou (Author), Justin D. Crane (Author), Julian M. Yabut (Author), Bente Kiens (Author), Derek M. Erion (Author), Adhiraj Lanba (Author), James G. Granneman (Author), Saswata Talukdar (Author), Gregory R. Steinberg (Author)
• Format: Book
• Published: Elsevier, 2017-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Fibroblast growth factor 21 (FGF21) shows great potential for the treatment of obesity and type 2 diabetes, as its long-acting analogue reduces body weight and improves lipid profiles of participants in clinical studies; however, the intracellular mechanisms mediating these effects are po...